Innovating CAR T-cell therapy as a potential paradigm shift in the treatment of autoimmune diseases.

Over 80 known autoimmune diseases. Suboptimal treatments. Serious long-term side effects.

Autoimmune diseases affect as many as 50 million people in the U.S.1 More than 80 known autoimmune diseases exist with suboptimal treatment and no cures, representing a leading cause of death and disability. Despite the tremendous progress in the clinical management of autoimmune diseases, many patients do not respond to the currently used treatments.2

There is a need for new therapeutic paradigms that can result in sustained, treatment-free remission and alleviate risks of long-term toxicities.

1. https://autoimmune.org › 1-in-5-Brochure. Accessed on January 22, 2024
2. Schett G, et al. Lancet. 2023;402:2034-2044

Current treatments are inadequate

There are few treatment options for autoimmune diseases and most patients undergo lifelong treatments which may have sub-optimal activity and are associated with risk of treatment-related toxicities. Autoimmune diseases may also require extreme, broadly immunosuppressive approaches (for example, corticosteroids or calcineurin inhibitors) which can leave patients with dampened immune responses, rendering them susceptible to infections and malignancies.


More is needed to improve the lives of patients living with autoimmune diseases

Kyverna aims to successfully apply cell therapy to autoimmunity. We believe that Kyverna’s engineered cells have the potential to address the underlying mechanisms of autoimmune diseases with the additional benefits of improving safety and tolerability by reducing toxicity associated with current treatments.

Our goal is to demonstrate the clinical potential of Kyverna’s engineered T-cell therapies as safe and effective to ideally achieve a sustained, treatment-free remission while alleviating the risks of long-term toxicities.

Learn more about CAR T-cell therapy for autoimmune diseases